GLP-1 receptor agonists in type 1 diabetes: a proof-of-concept approach

[1] Inzucchi SE(2015)Management of hyperglycemia in type 2 diabetes, 2015: a patient-centered approach: update to a position statement of the American Diabetes Association and the European Association for the Study of Diabetes Diabetes Care 38 140-149

[2] Bergenstal RM(2013)Pharmacology, physiology, and mechanisms of incretin hormone action Cell Metab 17 819-837

[3] Buse JB(2001)Combination of continuous subcutaneous infusion of insulin and octreotide in Type 1 diabetic patients Diab Res Clin Pract 51 97-105

[4] Diamant M(2009)Treatment of type 1 diabetic patients with glucagon-like peptide-1 (GLP-1) and GLP-1R agonists Curr Diabetes Rev 5 266-275

[5] Ferrannini E(2013)Liraglutide as additional treatment to insulin in obese patients with type 1 diabetes mellitus EndocrPract 19 963-967

[6] Nauck M(2013)Type 1 diabetes treatment beyond insulin: role of GLP-1 analogs J Investig Med 61 40-44

[7] Peters AL(2011)Liraglutide as additional treatment for type 1 diabetes Eur J Endocrinol 165 77-84

[8] Tsapas A(2013)Addition of exenatide or sitagliptin to insulin in new onset type 1 diabetes: a randomized, open label study Diab Res Clin Pract 100 55-58

[9] Wender R(2009)Effects of exenatide alone and in combination with daclizumab on beta-cell function in long-standing type 1 diabetes Diabetes Care 32 2251-2257

[10] Matthews DR(2014)Once-weekly exenatide as adjunct treatment of type 1 diabetes mellitus in patients receiving continuous subcutaneous insulin infusion therapy Can J Diabets 38 269-272

[1] Inzucchi SE(2015)Management of hyperglycemia in type 2 diabetes, 2015: a patient-centered approach: update to a position statement of the American Diabetes Association and the European Association for the Study of Diabetes Diabetes Care 38 140-149

[2] Bergenstal RM(2013)Pharmacology, physiology, and mechanisms of incretin hormone action Cell Metab 17 819-837

[3] Buse JB(2001)Combination of continuous subcutaneous infusion of insulin and octreotide in Type 1 diabetic patients Diab Res Clin Pract 51 97-105

[4] Diamant M(2009)Treatment of type 1 diabetic patients with glucagon-like peptide-1 (GLP-1) and GLP-1R agonists Curr Diabetes Rev 5 266-275

[5] Ferrannini E(2013)Liraglutide as additional treatment to insulin in obese patients with type 1 diabetes mellitus EndocrPract 19 963-967

[6] Nauck M(2013)Type 1 diabetes treatment beyond insulin: role of GLP-1 analogs J Investig Med 61 40-44

[7] Peters AL(2011)Liraglutide as additional treatment for type 1 diabetes Eur J Endocrinol 165 77-84

[8] Tsapas A(2013)Addition of exenatide or sitagliptin to insulin in new onset type 1 diabetes: a randomized, open label study Diab Res Clin Pract 100 55-58

[9] Wender R(2009)Effects of exenatide alone and in combination with daclizumab on beta-cell function in long-standing type 1 diabetes Diabetes Care 32 2251-2257

[10] Matthews DR(2014)Once-weekly exenatide as adjunct treatment of type 1 diabetes mellitus in patients receiving continuous subcutaneous insulin infusion therapy Can J Diabets 38 269-272